Your browser doesn't support javascript.
loading
BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer.
Valanparambil, Rajesh M; Lai, Lilin; Johns, Margaret A; Davis-Gardner, Meredith; Linderman, Susanne L; McPherson, Tarrant Oliver; Chang, Andres; Akhtar, Akil; Gamarra, Estefany L Bocangel; Matia, Hayley; McCook-Veal, Ashley A; Switchenko, Jeffrey; Nasti, Tahseen H; Green, Felicia; Saini, Manpreet; Wieland, Andreas; Pinsky, Benjamin A; Solis, Daniel; Dhodapkar, Madhav V; Carlisle, Jennifer; Ramalingam, Suresh; Ahmed, Rafi; Suthar, Mehul S.
Afiliação
  • Valanparambil RM; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
  • Lai L; Department of Microbiology and Immunology, Emory University, Atlanta, GA, USA.
  • Johns MA; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
  • Davis-Gardner M; Department of Pediatrics, Emory University, Atlanta, GA, USA.
  • Linderman SL; Emory National Primate Center, Atlanta, GA, USA.
  • McPherson TO; Winship Cancer Institute of Emory University, Atlanta, GA, USA.
  • Chang A; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
  • Akhtar A; Department of Pediatrics, Emory University, Atlanta, GA, USA.
  • Gamarra ELB; Emory National Primate Center, Atlanta, GA, USA.
  • Matia H; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
  • McCook-Veal AA; Department of Microbiology and Immunology, Emory University, Atlanta, GA, USA.
  • Switchenko J; Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, USA.
  • Nasti TH; Biostatistics Shared Resource, Winship Cancer Institute, Emory University, Atlanta, USA.
  • Green F; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
  • Saini M; Department of Microbiology and Immunology, Emory University, Atlanta, GA, USA.
  • Wieland A; Winship Cancer Institute of Emory University, Atlanta, GA, USA.
  • Pinsky BA; Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA.
  • Solis D; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
  • Dhodapkar MV; Department of Microbiology and Immunology, Emory University, Atlanta, GA, USA.
  • Carlisle J; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
  • Ramalingam S; Department of Microbiology and Immunology, Emory University, Atlanta, GA, USA.
  • Ahmed R; Winship Cancer Institute of Emory University, Atlanta, GA, USA.
  • Suthar MS; Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, USA.
NPJ Vaccines ; 8(1): 179, 2023 Nov 21.
Article em En | MEDLINE | ID: mdl-37990024
ABSTRACT
This study reports that most patients with NSCLC had a significant increase in the nAb response to the currently circulating Omicron variants after bivalent booster vaccination and had Ab titers comparable to healthy participants. Interestingly, though the durability of the nAb response persisted in most of the healthy participants, patients with NSCLC had significantly reduced nAb titers after 4-6 months of vaccination. Our data highlight the importance of COVID-19 bivalent booster vaccination as the standard of care for patients with NSCLC given the evolution of new variants of concern.
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article